CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

First International Summit on Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Opening Session Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Welcome and Introduction to Vi3C

Apr

Today In Oncology

Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer

Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Improving Early Detection of Pancreatic Cancer in High-Risk Patients

Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Related Videos